# A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

> **NCT01347710** · PHASE3 · COMPLETED · sponsor: **Lantheus Medical Imaging** · enrollment: 795 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Flurpiridaz F18
- **DRUG:** 99mTechnicium (sestamibi or tetrofosmin)

## Key facts

- **NCT ID:** NCT01347710
- **Lead sponsor:** Lantheus Medical Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-09
- **Target enrollment:** 795 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01347710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01347710, "A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01347710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*